Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging

Autor: Xenofon Baraliakos, Jerney de Jongh, Denis Poddubnyy, Gerben J. C. Zwezerijnen, Robert Hemke, Sophie Glatt, Stevan Shaw, Lucian Ionescu, Assem el Baghdady, Joanne Mann, Ralph Paul Maguire, Tom Vaux, Natasha de Peyrecave, Marga Oortgiesen, Dominique Baeten, Conny van der Laken

Publikováno v: Therapeutic Advances in Musculoskeletal Disease, Vol 16 (2024)

Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation is possible using 18 F-fluoride posi

Externí odkaz: https://doaj.org/article/e1c9ce375eb047a9b8433d9b2c1e2e5f

Effects of anti-interleukin-17 treatment on osteoblastic activity as assessed by ¹⁸F-sodium fluoride positron emission tomography/computed tomography in ankylosing spondylitis: a case report.

Autor: Ushio, Y¹ (AUTHOR), Wakiya, R¹ (AUTHOR) wakiya.risa@kagawa-u.ac.jp, Kameda, T¹ (AUTHOR), Nakashima, S¹ (AUTHOR), Shimada, H¹ (AUTHOR), Miyagi, T¹ (AUTHOR), Sugihara, K¹ (AUTHOR), Mino, R¹ (AUTHOR), Mizusaki, M¹ (AUTHOR), Chujo, K¹ (AUTHOR), Kagawa, R¹ (AUTHOR), Yamaguchi, H¹ (AUTHOR), Yamamoto, Y² (AUTHOR), Norikane, T² (AUTHOR), Nishiyama, Y² (AUTHOR), Kadowaki, N¹ (AUTHOR), Dobashi, H¹ (AUTHOR)

Publikováno v: Scandinavian Journal of Rheumatology. Nov2023, Vol. 52 Issue 6, p710-712. 3p.

Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging.

Autor: Baraliakos X; Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany., de Jongh J; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Amsterdam, The Netherlands., Poddubnyy D; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany., Zwezerijnen GJC; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands., Hemke R; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands., Glatt S; UCB, Brussels, Belgium., Shaw S; UCB, Slough, UK., Ionescu L; UCB, Brussels, Belgium., El Baghdady A; UCB, Slough, UK.; Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK., Mann J; UCB, Slough, UK., Maguire RP; UCB, Brussels, Belgium., Vaux T; UCB, Slough, UK., de Peyrecave N; UCB, Brussels, Belgium., Oortgiesen M; UCB, Raleigh, NC, USA., Baeten D; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam.; UMC, Amsterdam, The Netherlands UCB, Slough, UK., van der Laken C; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, Amsterdam, The Netherlands.

Publikováno v: Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2024 Nov 28; Vol. 16, pp. 1759720X241293944. Date of Electronic Publication: 2024 Nov 28 (Print Publication: 2024).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.